Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Large B-Cell, Diffuse × avelumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 27 Carcinoma, Transitional Cell 25 Urinary Bladder Neoplasms 23 Neoplasms 20 Carcinoma, Merkel Cell 20 Carcinoma, Renal Cell 18 Neoplasm Metastasis 17 Colorectal Neoplasms 15 Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 12 Ovarian Neoplasms 12 Triple Negative Breast Neoplasms 8 Head and Neck Neoplasms 8 Pancreatic Neoplasms 7 Stomach Neoplasms 6 Melanoma 6 Recurrence 5 Prostatic Neoplasms 5 Carcinoma, Hepatocellular 5 Ureteral Neoplasms 4 Small Cell Lung Carcinoma 4 Neuroendocrine Tumors 4 Glioblastoma 4 Carcinoma, Squamous Cell 4 Uterine Cervical Neoplasms 3 Urethral Neoplasms 3 Turcot syndrome 3 Skin Neoplasms 3 Sarcoma 3 Lymphoma 3

Interventions

Rituximab 369 Cyclophosphamide 320 Vincristine 160 Prednisone 160 Doxorubicin 158 Etoposide 146 Filgrastim 99 Peripheral Blood Stem Cell Transplantation 97 Lenalidomide 91 fludarabine phosphate 82 Radiotherapy 73 Cytarabine 69 Gemcitabine 66 Mycophenolic Acid 57 Cyclosporine 55 Melphalan 54 Methotrexate 52 Ifosfamide 49 Busulfan 47 fludarabine 46 Carmustine 46 Whole-Body Irradiation 44 Carboplatin 42 Oxaliplatin 41 Tacrolimus 40 polatuzumab vedotin 36 Dexamethasone 36 Antilymphocyte Serum 36 ibrutinib 34 Magnetic Resonance Spectroscopy 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02951156 2020-12-17

Javelin DLBCL

Pfizer

Phase 3 Terminated

29 enrolled 24 charts

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡